Long-term treatment of chronic plaque psoriasis with calcipotriol

Poyner, T; Hughes, I. W.; Dass, B; Adnitt, P. I.

doi:10.3109/09546639309089517

Cited by 39 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three uncontrolled studies have investigated the long-term use of calcipotriol [8,9,10], and concluded that efficacy was maintained over 48 weeks. There is a perception of tachyphylaxis with long-term corticosteroid use [13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

et al. 2006

View full text Add to dashboard Cite

Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The long-term efficacy and safety of calcipotriol in the treatment of psoriasis have been well documented [8,9,10]. The primary objective of this study was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks in the treatment of psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

et al. 2006

View full text Add to dashboard Cite

show abstract

“…In addition, Bourke et al 13 observed hypercalcemia in five of 16 patients with topical application of up to 360 g/week for 2 weeks, and reported topical dose-dependent increases in serum calcium levels. On the other hand, Poyner et al 14 reported no hypercalcemia, renal disorders, or liver disorders in 203 psoriasis patients over the course of 48 weeks of observations in a multicenter open-label study, in which the average dose for the 6 weeks was 16.5 g/week, followed by a gradual reduction in topical dose thereafter. There was no concomitant systemic therapy, and patients with liver disorders or renal disorders were excluded, as were patients with active psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Safety profiles of topical vitamin D3 in psoriasis patients: a retrospective large-scale study

Yamamoto¹,

Furuhashi²,

Matsumoto³

et al. 2012

PTT

View full text Add to dashboard Cite

Topical vitamin D 3 ointments are widely used to treat psoriasis, sometimes in combination with cyclosporine, phototherapy, and biologic agents. However, the risk factors for hypercalcemia resulting from these ointments, and interactions with underlying disorders and age are unclear. We performed a retrospective study of psoriasis patients at Nagoya City University Hospital between January 1, 2004, and December 31, 2009, treated with a vitamin D 3 -containing topical drug, either calcipotriol, maxacalcitol, or tacalcitol. Data from blood samples and clinical scores collected during routine visits throughout the study period were analyzed. We assessed changes in the serum calcium levels over time in association with age, liver dysfunction, renal dysfunction, concomitant medication, and concomitant therapy. Serum calcium levels were significantly lower in the calcipotriol group than in the maxacalcitol group (P , 0.05), regardless of other factors, at the observation period. Calcipotriol was associated with lower serum calcium levels than maxacalcitol in patients $ 65 years (P , 0.05), those with renal disease (P = 0.0362), and those with liver disease (P = 0.0255). Only three patients using calcipotriol developed hypercalcemia that did not seem to be related to the treatment. Hypercalcemia was observed in 10 patients using maxacalcitol, although serum calcium levels rapidly recovered when use was discontinued. Only one patient using tacalcitol developed hypercalcemia. Hypercalcemia tended to occur in patients with conditions in which the skin is more vulnerable, even at standard doses; patients taking oral etretinate; patients requiring concomitant systemic therapy, even if the Psoriasis Area and Severity Index score was not severe; and patients with renal or liver dysfunction. These findings highlight the importance of the awareness of the risk factors for hypercalcemia in patients treated with topical vitamin D 3 ointment, and point to calcipotriol as the first-choice treatment for those over 65 years old, or those with renal or liver disease.

show abstract

“…In randomised, controlled trials lasting 6 or 8 weeks calcipotriol ointment (50µg/g) applied twice daily was as effective as but caused more skin irritation than 0.1% betamethasone ointment,6 , 7 was more effective and with fewer unwanted effects than short-contact dithranol cream8 and was more effective but with a higher incidence of skin irritation than 15% coal tar solution 9. In a multicentre, open, uncontrolled study of 144 patients calcipotriol, starting at a dose of 16.5g/week and finishing with 11.6g/week, continued to work for up to 50 weeks 10. Calcipotriol commonly causes transient skin irritation that rarely requires cessation of treatment.…”

Section: Topical Therapymentioning

confidence: 99%

The management of psoriasis

1996

DTB

View full text Add to dashboard Cite

show abstract

Long-term treatment of chronic plaque psoriasis with calcipotriol

Cited by 39 publications

References 15 publications

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis Vulgaris

Safety profiles of topical vitamin D3 in psoriasis patients: a retrospective large-scale study

The management of psoriasis

Contact Info

Product

Resources

About